When overexpressed, or treated with the PXR agonist, SR12813, PXR reduced the response in breast cancer cells to tamoxifen, cisplatin, and paclitaxel treatment, whereas its downregulation restored cell cycle regulation and apoptosis [47,48]. Here, NR1I2 is linked to breast carcinoma.